ArticleOpen forum infectious diseases2026
Genomic Surveillance of Respiratory Syncytial Virus in Sydney Reveals Rebound in Postpandemic Viral Diversity.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic Surveillance Uncovers a Shift in Respiratory Syncytial Virus Subtype Dominance and the Local Expansion of Subclade B.D.E.1.7.Open forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) transmission between 2020 and 2025 was impacted by COVID-19-related public health measures, resulting in unprecedented genomic bottlenecks, and postpandemic surges in clinical cases. We performed whole-genome sequencing of 100 infant RSV cases in Sydney during the 2024 winter season. Phylogenetic analysis revealed a marked rebound in genomic diversity compared with prior seasons, driven by multiple international lineage introductions. No known therapeutic-resistance mutations were detected. These findings provide a preintervention baseline for monitoring RSV evolution under emerging therapeutic selection pressures in Australia, with the national rollout of the recently approved maternal vaccine (Abrysvo) and monoclonal antibody (nirsevimab) through the RSV Mother and Infant Protection Program commencing in 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.